Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors: P-GP in Brain Tumors

86Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Multidrug resistance (MDR) is associated with the expression of P-glycoprotein (P-gp), an ATP-dependent transporter which expels anti-cancer drugs from cells. In the present study, MDR1 P-gp was immunodetected by Western blot analysis in 60 human brain tumors, including meningiomas, schwannomas, low-grade gliomas (astrocytomas, pilocytic astrocytomas) and high-grade gliomas (anaplastic astrocytomas, glioblastomas and anaplastic oligodendrogliomas). Most samples from primary tumors expressed P-gp at the same levels as normal brain tissue except for schwannomas, in which levels were reduced by 65%, and meningiomas, in which levels were more than 10-fold higher in 7 of 10 samples. P-gp levels were 70% and 95% lower in brain metastases from melanomas and lung adenocarcinomas, respectively, than in normal brain tissue. These results indicate that the majority of primary brain tumors express MDR1 P-gp and that its high expression levels in meningiomas may be a marker for this type of brain tumor. © 2001 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Demeule, M., Shedid, D., Beaulieu, É., Del Maestro, R. F., Moghrabi, A., Ghosn, P. B., … Béliveau, R. (2001). Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors: P-GP in Brain Tumors. International Journal of Cancer, 93(1), 62–66. https://doi.org/10.1002/ijc.1306

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free